R&D NETWORK – conjugated antibodies

/in , /by

Event Details

The first R&D Network in 2015 will take a closer look at antibody drug conjugates and treatment options, the use in clinical treatment and exciting new conjugated antibodies in pipeline.

The registration is  now closed. Send an email to Marthe Brovold Løberg if you would like to join or have to cancel.

The seminar and light refreshments afterwards are free of charge, but please note that we will issue a no-show fee. Let us know 24 hours prior to the event, if you can not come.

We look forward to an interesting meeting.

Member companies Takeda Nycomed and Roche Norge AS kindly support the R&D Network

 
PROGRAM /Download program

14:00–14:15 Registration and coffee
14:15–14:30 Welcome and introduction- Arne Kolstad, MD, Dept. of Oncology, OUS Radiumhospitalet
14:30–15:00 International key note speaker:“Development of Antibody Drug Conjugates in hematologic malignancies”- Dr Rodney B. Smith MD, Senior International Medical Director, Roche
15:00–15:40 International key note speaker:”Antibody-drug conjugates and new treatment options”- Petter Veiby, PhD, global head of BioTherapeutics, Oncology DDU at Takeda Pharmaceuticals International, US.Q&A session10 min coffee break
16:00–16:30 Clinical perspectives:“Antibody-drug conjugates in treatment of lymphoma cancer patients”- Alexander Fosså, MD, Dept. of Oncology, OUS Radiumhospitalet
16:30–17:00 The biotech perspective:“Phase I study with new radioimmunoconjugate in indolent non-Hodgkin`s lymphomas. A Nordic Nanovector study”- Arne Kolstad, MD, Dept. of Oncology, OUS Radiumhospitalet
17:00–18:00 Networking session with light refreshments